On Apr. 13, 2020, Bausch Health announced it has initiated a clinical trial program in Canada evaluating an investigational use of VIRAZOLEﾮ (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. Because ribavirin is a synthetic nucleoside that works to stop viral replication, VIRAZOLE may be effective in reducing the severity of COVID-19 infection.